Cholangiocarcinoma (often called bile duct cancer) is a type of cancer that develops in the bile ducts—the tubes that carry bile from the liver to the gallbladder and small intestine.
🧠 What exactly is it?
Cholangiocarcinoma is a malignant tumor arising from the epithelial cells lining the bile ducts. These ducts are part of the hepatobiliary system, and their job is to transport bile, which helps digest fats.
📍 Types (based on location)
We classify it anatomically into three main types:
- Intrahepatic cholangiocarcinoma
- Occurs inside the liver
- Perihilar cholangiocarcinoma (also called Klatskin tumor)
- Occurs at the junction where the right and left hepatic ducts meet
- Distal cholangiocarcinoma
- Occurs closer to the small intestine
⚠️ Causes and risk factors
The exact cause is often unclear, but several risk factors are known:
- Chronic bile duct inflammation
- Primary sclerosing cholangitis (PSC)
- Liver fluke infections (common in parts of Asia)
- Hepatitis B or C
- Cirrhosis
- Congenital bile duct abnormalities
🧪 Symptoms
Early stages are often silent. When symptoms appear, they may include:
- Jaundice (yellowing of skin and eyes)
- Dark urine, pale stools
- Itching (pruritus)
- Abdominal pain (right upper quadrant)
- Weight loss and fatigue
- Fever (sometimes)
🔬 Diagnosis
Diagnosis typically involves:
- Blood tests (including liver function tests, tumor markers like CA 19-9)
- Imaging: ultrasound, CT scan, MRI/MRCP
- Endoscopic procedures (ERCP)
- Biopsy for definitive confirmation
🏥 Treatment
Management depends on stage and location:
1. Surgical resection (curative option)
- Best chance for cure if detected early
2. Liver transplantation
- Selected cases (especially perihilar tumors)
3. Palliative treatments
- Biliary drainage (stents) to relieve obstruction
- Chemotherapy (e.g., gemcitabine + cisplatin)
- Radiation therapy
📉 Prognosis
- Often poor, because it’s usually diagnosed late
- 5-year survival varies widely depending on resectability
- Early detection significantly improves outcomes
🧠 Surgical perspective (important points)
- Resectability depends on vascular involvement and liver reserve
- Margin-negative (R0) resection is critical
- Multidisciplinary approach is essential (surgery, oncology, radiology)